Zydus Lifesciences has informed that it enclosed two press releases, both dated February 20, 2023 titled ‘Zydus receives tentative approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 mg and 600 mg’ and ‘Zydus receives tentative approval from the USFDA for Canagliflozin and Metformin Hydrochloride Tablets’.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.15 |
| Dr. Reddys Lab | 1236.65 |
| Cipla | 1236.45 |
| Zydus Lifesciences | 938.75 |
| Lupin | 2328.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: